Vitamin E and aspirin delay heart disease in mice even with high cholesterol levels

October 18, 2001

Penn study finds plaque production in blood vessels is reduced more than 80 percent

A combination of the anti-oxidant Vitamin E and a cox inhibitor such as aspirin significantly delays the development of atherosclerosis in mice even when their cholesterol levels remain high, according to research by scientists at the University of Pennsylvania School of Medicine.

In the study, the production of plaque in the blood vessels of the mice was lowered more than 80 percent, said Domenico Pratico, MD, research assistant professor in Penn's Department of Pharmacology and the lead investigator in the research. The findings are published this week in Circulation, a journal of the American Heart Association.

"We think this is a therapy regimen suitable for clinical trials," Pratico said. "The implication is that if you combine an antioxidant with even a low dose of aspirin, you might be able to obtain primary prevention of atherosclerosis without reducing cholesterol. This is something that might be used by individuals who cannot take cholesterol-reducing medication, and it would be a very inexpensive way to prevent such a deadly disease."

Pratico and his colleagues used a group of mice that had been genetically engineered to produce high cholesterol and atherosclerotic lesions similar to human plaques, in a series of studies that examined how the mammals' cardiovascular systems would respond to Vitamin E and aspirin or similar drugs when they developed the disease.

The first test group was administered a daily dose of Vitamin E that would have equaled 800 units in human subjects. "We found that Vitamin E reduced oxidative stress, which is known to be increased in atherosclerosis, to the point that it was suppressed in the mice," Pratico said. "It also reduced atherosclerosis by 65 percent. And this was accomplished without lowering the cholesterol levels."

When the second test group was administered the same dose of Vitamin E along with a dose of indomethacin that would have equalled 25 milligrams in humans, the results were even more compelling: "We found the synergistic effect from Vitamin E and indomethacin resulted in an 85 percent reduction of atherosclerosis," Pratico said.

"Atherosclersis is a complex disease, and high cholesterol is one of the many factors involved in its pathogenesis. Oxidative stress and inflammation are probably as important as cholesterol, if we can delay or prevent its onset with this combination of drugs," Pratico said. "We now have a scientific basis for evaluating in humans this unexpected therapy in the prevention of such a common and expensive disease."
-end-
The work was funded by the National Institutes of Health and the American Heart Association.

Pratico's collaborators in the research included: Tillman Cyrus, MD; Lina X. Tang, B.Sc., and Garret FitzGerald, MD, all of Penn's Center for Experimental Therapeutics, and Joshua Rokach, PhD, of the Claude Pepper Institute of the Florida Institute of Technology in Melbourne, FLA.

University of Pennsylvania School of Medicine

Related Cholesterol Articles from Brightsurf:

Cholesterol's effects on cellular membranes
The findings have far-reaching implications in the general understanding of disease, the design of drug delivery methods, and many other biological applications that require specific assumptions about the role of cholesterol in cell membranes.

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

Microbes might manage your cholesterol
Researchers discover a link between human blood cholesterol levels and a gene in the microbiome that could one day help people manage their cholesterol through diet, probiotics, or entirely new types of treatment.

Experimental cholesterol-lowering drug effective at lowering bad cholesterol, study shows
Twice-yearly injections of an experimental cholesterol-lowering drug, inclisiran, were effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol, in patients already taking the maximum dose of statin drugs, according to data of the ORION-10 trial presented Saturday, Nov.

Rethinking how cholesterol is integrated into cells
Cholesterol is best known in connection with cardiovascular disease, but cholesterol is also vital for many fundamental processes in the body.

Seed oils are best for LDL cholesterol
Using a statistical technique called network meta-analysis, researchers have combined the results of dozens of studies of dietary oils to identify those with the best effect on patients' LDL cholesterol and other blood lipids.

Cholesterol leash: Key tethering protein found to transport cellular cholesterol
Cholesterol is an essential component of living organisms, but the mechanisms that transport cholesterol inside the cell are poorly understood.

New way to treat cholesterol may be on the horizon
A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol.

How low should LDL cholesterol go?
New analysis shows that in a high-risk population, achieving ultra-low LDL cholesterol levels, down to <10 mg/dL, safely results in additional lowering of risk of cardiovascular events.

Does boosting 'good' cholesterol really improve your health?
A new review addresses the mysteries behind 'good' HDL cholesterol and why boosting its levels does not necessarily provide protection from cardiovascular risk for patients.

Read More: Cholesterol News and Cholesterol Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.